GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » EBIT per Share

Nanopharmaceutics (Nanopharmaceutics) EBIT per Share : $-0.01 (TTM As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics EBIT per Share?

Nanopharmaceutics's EBIT per Share for the three months ended in Sep. 2018 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nanopharmaceutics's EBIT per Share or its related term are showing as below:

TGRP's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Nanopharmaceutics's EBIT for the three months ended in Sep. 2018 was $-0.08 Mil.

Nanopharmaceutics EBIT per Share Historical Data

The historical data trend for Nanopharmaceutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics EBIT per Share Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
EBIT per Share
- -0.01 -0.01

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Nanopharmaceutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nanopharmaceutics's EBIT per Share for the fiscal year that ended in Dec. 2017 is calculated as

EBIT per Share(A: Dec. 2017 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.217/163.329
=-0.01

Nanopharmaceutics's EBIT per Share for the quarter that ended in Sep. 2018 is calculated as

EBIT per Share(Q: Sep. 2018 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.078/163.329
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics  (OTCPK:TGRP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nanopharmaceutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanopharmaceutics (Nanopharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » EBIT per Share
Comparable Companies
MIII TSE:5363 TSE:7721 TSE:5821 TSX:AEF SDOIA DFM:GGICO SAU:2120 ABWN COL:RICH.N0000 CNAC MIL:SPRT XSGO:QUEMCHI TSE:3353 COL:VONE.N0000 XPAE:APIC MIL:CRS ELEC ATH:MIG XCNQ:MARI
Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Website
https://www.nanopharmaceutics.com
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.